[go: up one dir, main page]

HRP20191500T1 - Protutijela protiv cd47 i postupci njihove upotrebe - Google Patents

Protutijela protiv cd47 i postupci njihove upotrebe Download PDF

Info

Publication number
HRP20191500T1
HRP20191500T1 HRP20191500T HRP20191500T1 HR P20191500 T1 HRP20191500 T1 HR P20191500T1 HR P20191500 T HRP20191500 T HR P20191500T HR P20191500 T1 HRP20191500 T1 HR P20191500T1
Authority
HR
Croatia
Prior art keywords
seq
set forth
sequence set
cdr1
cdr2
Prior art date
Application number
Other languages
English (en)
Inventor
Brendan Eckelman
John Timmer
Amir Razai
Quinn Deveraux
Kyle Jones
Peter L Nguy
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48947976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191500(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of HRP20191500T1 publication Critical patent/HRP20191500T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (12)

1. Izolirano monoklonsko protutijelo, ili njegov imunološki aktivni fragment, koje se veže na ljudski CD47, naznačeno time što se protutijelo, ili njegov imunološki aktivni fragment, veže na diskontinuirani epitop na CD47, gdje diskontinuirani epitop sadrži aminokiselinske ostatke Y37, K39, K41, K43, G44, R45, D46, D51, H90, N93, E97, T99, E104, te E106 u CD47 kada su obrojčani kao u SEQ ID NO: 147, te što protutijelo, ili njegov imunološki aktivni fragment, sprječava međudjelovanje CD47 s proteinom regulatorom signala α (SIRPα) i ne uzrokuje značajnu razinu aglutiniranja stanica nakon primjene.
2. Protutijelo, ili njegov imunološki aktivni fragment, u skladu s patentnim zahtjevom 1, naznačeno time što je protutijelo, ili njegov imunološki aktivni fragment, kimerno ili humanizirano.
3. Protutijelo, ili njegov imunološki aktivni fragment, u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što protutijelo, ili njegov imunološki aktivni fragment, potiče fagocitozu koju vrši makrofag stanice koja eksprimira CD47.
4. Protutijelo, ili njegov imunološki aktivni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što protutijelo, ili njegov imunološki aktivni fragment, pripada izotipu IgG, kojeg se bira između grupe koja se sastoji od IgG 1 izotip, IgG2 izotip, IgG3 izotip, i IgG4 izotip.
5. Protutijelo, ili njegov imunološki aktivni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što protutijelo, ili njegov imunološki aktivni fragment, pripada izotipu IgG, kojeg se bira između IgG4P i IgG4PE.
6. Protutijelo, ili njegov imunološki aktivni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačeno time što protutijelo, ili njegov imunološki aktivni fragment, sadrži: (i) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 72, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 53, VL CDR2 slijed iznijet u SEQ ID NO: 71, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (ii) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 53, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (iii) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 67, VL CDR2 slijed iznijet u SEQ ID NO: 69, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (iv) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 67, VL CDR2 slijed iznijet u SEQ ID NO: 70, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (v) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 68, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (vi) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 72, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 68, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (vii) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 72, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 68, VL CDR2 slijed iznijet u SEQ ID NO: 71, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (viii) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 76, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 68, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (ix) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 76, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 68, VL CDR2 slijed iznijet u SEQ ID NO: 71, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (x) VH CDR1 slijed iznijet u SEQ ID NO: 50, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 77, VL CDR1 slijed iznijet u SEQ ID NO: 53, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (xi) VH CDR1 slijed iznijet u SEQ ID NO: 57, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 53, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (xii) VH CDR1 slijed iznijet u SEQ ID NO: 60, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 53, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55; (xiii) VH CDR1 slijed iznijet u SEQ ID NO: 61, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 53, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55; ili (xiv) VH CDR1 slijed iznijet u SEQ ID NO: 62, VH CDR2 slijed iznijet u SEQ ID NO: 51, VH CDR3 slijed iznijet u SEQ ID NO: 52, VL CDR1 slijed iznijet u SEQ ID NO: 53, VL CDR2 slijed iznijet u SEQ ID NO: 54, i VL CDR3 slijed iznijet u SEQ ID NO: 55.
7. Protutijelo, ili njegov imunološki aktivni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačeno time što protutijelo, ili njegov imunološki aktivni fragment, sadrži: (i) VH slijed iznijet u SEQ ID NO: 5, i VL slijed iznijet u SEQ ID NO: 31; (ii) VH slijed iznijet u SEQ ID NO: 5, i VL slijed iznijet u SEQ ID NO: 32; (iii) VH slijed iznijet u SEQ ID NO: 7, i VL slijed iznijet u SEQ ID NO: 33; (iv) VH slijed iznijet u SEQ ID NO: 7, i VL slijed iznijet u SEQ ID NO: 34; (v) VH slijed iznijet u SEQ ID NO: 7, i VL slijed iznijet u SEQ ID NO: 35; (vi) VH slijed iznijet u SEQ ID NO: 7, i VL slijed iznijet u SEQ ID NO: 36; (vii) VH slijed iznijet u SEQ ID NO: 7, i VL slijed iznijet u SEQ ID NO: 37; (viii) VH slijed iznijet u SEQ ID NO: 7, i VL slijed iznijet u SEQ ID NO: 38; (ix) VH slijed iznijet u SEQ ID NO: 7, i VL slijed iznijet u SEQ ID NO: 39; (x) VH slijed iznijet u SEQ ID NO: 7, i VL slijed iznijet u SEQ ID NO: 43; (xi) VH slijed iznijet u SEQ ID NO: 8, i VL slijed iznijet u SEQ ID NO: 39; (xii) VH slijed iznijet u SEQ ID NO: 11, i VL slijed iznijet u SEQ ID NO: 42; (xiii) VH slijed iznijet u SEQ ID NO: 11, i VL slijed iznijet u SEQ ID NO: 43; (xiv) VH slijed iznijet u SEQ ID NO: 11, i VL slijed iznijet u SEQ ID NO: 44; (xv) VH slijed iznijet u SEQ ID NO: 11, i VL slijed iznijet u SEQ ID NO: 47; (xvi) VH slijed iznijet u SEQ ID NO: 15, i VL slijed iznijet u SEQ ID NO: 43; (xvii) VH slijed iznijet u SEQ ID NO: 15, i VL slijed iznijet u SEQ ID NO: 44; (xviii) VH slijed iznijet u SEQ ID NO: 16, i VL slijed iznijet u SEQ ID NO: 35; (xix) VH slijed iznijet u SEQ ID NO: 17, i VL slijed iznijet u SEQ ID NO: 35; (xx) VH slijed iznijet u SEQ ID NO: 20, i VL slijed iznijet u SEQ ID NO: 35; (xxi) VH slijed iznijet u SEQ ID NO: 21, i VL slijed iznijet u SEQ ID NO: 35; (xxii) VH slijed iznijet u SEQ ID NO: 22, i VL slijed iznijet u SEQ ID NO: 35; (xxiii) VH slijed iznijet u SEQ ID NO: 27, i VL slijed iznijet u SEQ ID NO: 35; (xiv) VH slijed iznijet u SEQ ID NO: 28, i VL slijed iznijet u SEQ ID NO: 35; (xv) VH slijed iznijet u SEQ ID NO: 29, i VL slijed iznijet u SEQ ID NO: 35; ili (xvi) VH slijed iznijet u SEQ ID NO: 30, i VL slijed iznijet u SEQ ID NO: 35.
8. Farmaceutski pripravak, naznačen time što sadrži protutijelo, ili njegov imunološki aktivni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 7, kao i nosač.
9. Protutijelo, ili njegov imunološki aktivni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačeno time što je namijenjeno upotrebi u postupku ublažavanja simptoma raka ili drugog neoplastičnog stanja kod subjekta.
10. Protutijelo, ili njegov imunološki aktivni fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 9, naznačeno time što je subjekt čovjek.
11. Protutijelo, ili njegov imunološki aktivni fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačeno time što postupak dodatno uključuje primjenu kemoterapije.
12. Protutijelo, ili njegov imunološki aktivni fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačeno time što postupak dodatno uključuje primjenu radioterapije.
HRP20191500 2012-02-06 2013-02-06 Protutijela protiv cd47 i postupci njihove upotrebe HRP20191500T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261595216P 2012-02-06 2012-02-06
US201261659752P 2012-06-14 2012-06-14
PCT/US2013/024995 WO2013119714A1 (en) 2012-02-06 2013-02-06 Cd47 antibodies and methods of use thereof
EP13746964.9A EP2812443B1 (en) 2012-02-06 2013-02-06 Cd47 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20191500T1 true HRP20191500T1 (hr) 2019-11-29

Family

ID=48947976

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191500 HRP20191500T1 (hr) 2012-02-06 2013-02-06 Protutijela protiv cd47 i postupci njihove upotrebe

Country Status (35)

Country Link
US (4) US9045541B2 (hr)
EP (2) EP2812443B1 (hr)
JP (1) JP6273212B2 (hr)
KR (2) KR102338833B1 (hr)
CN (2) CN111533804A (hr)
AU (1) AU2013217114B2 (hr)
BR (1) BR112014019331A2 (hr)
CA (1) CA2863834A1 (hr)
CL (1) CL2014002086A1 (hr)
CO (1) CO7111273A2 (hr)
CR (1) CR20140406A (hr)
CY (1) CY1121911T1 (hr)
DK (1) DK2812443T3 (hr)
EA (1) EA034778B1 (hr)
EC (1) ECSP14016994A (hr)
ES (1) ES2743203T3 (hr)
HR (1) HRP20191500T1 (hr)
HU (1) HUE13746964T2 (hr)
IL (1) IL233934B (hr)
LT (1) LT2812443T (hr)
ME (1) ME03512B (hr)
MX (1) MX360772B (hr)
MY (1) MY169341A (hr)
NZ (1) NZ628314A (hr)
PE (1) PE20141908A1 (hr)
PH (1) PH12014501758B1 (hr)
PL (1) PL2812443T3 (hr)
PT (1) PT2812443T (hr)
RS (1) RS59159B1 (hr)
SG (2) SG11201404638SA (hr)
SI (1) SI2812443T1 (hr)
SM (1) SMT201900453T1 (hr)
UA (1) UA116772C2 (hr)
WO (1) WO2013119714A1 (hr)
ZA (1) ZA201405864B (hr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150553T1 (hr) 2009-05-15 2015-08-28 University Health Network Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju
HUE035281T2 (en) 2011-01-14 2018-05-02 Univ California Therapeutic antibodies against ror-1 protein and methods for use of same
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
PL2812443T3 (pl) 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
AU2013353763B2 (en) 2012-12-03 2018-09-13 Novimmune S.A. Anti-CD47 antibodies and methods of use thereof
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
EP2931751B1 (en) 2012-12-12 2020-02-05 Arch Oncology, Inc. Therapeutic cd47 antibodies
SMT201900623T1 (it) 2012-12-17 2020-01-14 Trillium Therapeutics Inc Trattamento di cellule di malattia cd47+ con fusioni sirp alpha-fc
SG11201506132PA (en) * 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN114917336A (zh) * 2013-03-15 2022-08-19 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
US11066467B2 (en) 2013-12-17 2021-07-20 Mhs Care-Innovation Llc Compositions and methods for treating ischemic heart disease
DK3828203T3 (da) * 2013-12-17 2024-07-15 Mhs Care Innovation Llc Sammensætninger og fremgangsmåder til behandling af fedtvævsopbygning
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
AU2015350190B2 (en) 2014-11-18 2021-08-05 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
CA2972604C (en) 2014-12-30 2023-07-04 Celgene Corporation Anti-cd47 antibodies and uses thereof
EP3247464B1 (en) * 2015-01-21 2019-09-18 The Board of Trustees of the Leland Stanford Junior University Use of tlr agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2016141328A2 (en) * 2015-03-04 2016-09-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd47
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
EP3349787A4 (en) 2015-09-18 2019-03-27 Arch Oncology, Inc. THERAPEUTIC CD47 ANTIBODIES
EP3353209B1 (en) 2015-09-21 2022-03-16 Erasmus University Medical Center Rotterdam Anti-cd47 antibodies and methods of use
KR102472087B1 (ko) 2016-01-11 2022-11-29 포티 세븐, 인코포레이티드 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
SI3442578T1 (sl) 2016-04-15 2022-05-31 The Board Of Trustees Of The Leland Standford Junior University Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka
US20200255515A1 (en) * 2016-05-09 2020-08-13 Celgene Corporation Cd47 antibodies and methods of use thereof
CN106084052B (zh) * 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
US12344669B2 (en) 2016-06-17 2025-07-01 Changchun Genescience Pharmaceutical Co., Ltd. Anti-CD47 monoclonal antibody and use thereof
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
BR112019000166A2 (pt) * 2016-07-06 2019-10-01 Celgene Corp anticorpos com baixa imunogenicidade e usos dos mesmos
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
CN107955071B (zh) * 2016-10-18 2021-03-26 上海赛远生物科技有限公司 人源抗人cd47抗体及其编码基因与应用
MX2019004691A (es) * 2016-10-20 2019-12-09 I Mab Biopharma Us Ltd Anticuerpos monoclonales cd47 novedosos y sus usos.
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
WO2018081897A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
WO2018095428A1 (zh) * 2016-11-28 2018-05-31 江苏恒瑞医药股份有限公司 Cd47抗体、其抗原结合片段及其医药用途
CA3051512A1 (en) * 2017-01-26 2018-08-02 Zlip Holding Limited Cd47 antigen binding unit and uses thereof
WO2018175790A1 (en) * 2017-03-22 2018-09-27 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
US11866507B2 (en) 2017-04-11 2024-01-09 Inhibrx, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
CN109096395B (zh) * 2017-06-20 2022-06-24 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
CA3070828A1 (en) 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction
MX2020001309A (es) * 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
CN117820498A (zh) * 2017-08-10 2024-04-05 盖立复诊断解决方案公司 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒
CA3072998A1 (en) 2017-08-18 2019-02-21 Ultrahuman Four Limited Binding agents
CN109422811A (zh) * 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
KR20200079511A (ko) 2017-11-01 2020-07-03 허밍버드 바이오사이언스 홀딩스 피티이. 엘티디. Cd47 항원-결합 분자
CN110573622A (zh) * 2017-11-10 2019-12-13 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白
MA51208A (fr) 2017-12-01 2020-10-07 Seattle Genetics Inc Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer
KR20200116109A (ko) * 2018-01-24 2020-10-08 난징 레전드 바이오테크 씨오., 엘티디. 상당한 적혈구 응집을 야기하지 않는 항-cd47 항체
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
JP2021520812A (ja) 2018-04-11 2021-08-26 インヒブルクス インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
CN110526972A (zh) * 2018-05-25 2019-12-03 江苏恒瑞医药股份有限公司 一种抗cd47抗体在制备治疗淋巴瘤的药物中的用途
CN110577597B (zh) 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
US11634490B2 (en) 2018-06-15 2023-04-25 Accurus Biosciences, Inc. Blocking antibodies against CD47 and methods of use thereof
CN110615841B (zh) * 2018-06-20 2022-01-04 瑞阳(苏州)生物科技有限公司 抗人cd47单克隆抗体及其应用
CN112638427A (zh) * 2018-06-29 2021-04-09 北卡罗莱纳州立大学 用于术后治疗的原位喷雾生物响应性免疫治疗凝胶
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
TWI830774B (zh) 2018-08-31 2024-02-01 大陸商南京聖和藥業股份有限公司 抗cd47抗體及其應用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3107369A1 (en) * 2018-10-31 2020-05-07 I-Mab Biopharma Us Limited Novel cd47 antibodies and methods of using same
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
WO2020114399A1 (zh) * 2018-12-03 2020-06-11 上海开拓者生物医药有限公司 Cd47抗体及其制备方法和应用
TW202104260A (zh) * 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
JP7561775B2 (ja) 2019-06-07 2024-10-04 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
PH12021553197A1 (en) * 2019-06-19 2022-11-07 Lepu Biopharma Co Ltd Anti-cd47 antibodies and uses thereof
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
CN110256565B (zh) * 2019-08-02 2021-03-23 天津大学 抗cd47纳米抗体突变体及其应用
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
HUE067160T2 (hu) 2019-09-18 2024-10-28 Lamkap Bio Alpha AG Bispecifikus antitestek CEACAM5 és CD3 ellen
AU2020353182A1 (en) * 2019-09-27 2022-04-14 Beijing Starmab Biomed Technology Ltd Monospecific and multi-specific antibodies
PL4045083T3 (pl) 2019-10-18 2024-05-13 Forty Seven, Inc. Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
CN114599681B (zh) * 2019-10-25 2024-01-09 上海药明生物技术有限公司 新型抗cd47抗体及其用途
EP4052040A1 (en) 2019-10-31 2022-09-07 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
SI4081305T1 (sl) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Spojine, ki modulirajo diacilglicerol kinazo
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
WO2021174091A1 (en) 2020-02-28 2021-09-02 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
US20230090014A1 (en) 2020-02-28 2023-03-23 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-cd47/anti-pd-l1 antibody and applications thereof
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022022662A1 (zh) * 2020-07-31 2022-02-03 百奥泰生物制药股份有限公司 Cd47抗体及其应用
WO2022076987A1 (en) 2020-10-07 2022-04-14 Celgene Corporation Bispecific antibody treatment of lymphoid malignant neoplasm conditions
EP4237451A1 (en) 2020-11-02 2023-09-06 Hummingbird Bioscience Pte. Ltd. Bcma/taci antigen-binding molecules
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
KR102757518B1 (ko) 2020-12-07 2025-01-21 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
US20240076412A1 (en) * 2021-01-05 2024-03-07 National Institute Of Biological Sciences, Beijing A bispecific antibody targeting gpc3 and cd47
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
JP2024512004A (ja) 2021-03-17 2024-03-18 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024518100A (ja) 2021-05-11 2024-04-24 マイエロイド・セラピューティクス，インコーポレーテッド ゲノム組込みのための方法および組成物
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US20250129155A1 (en) 2021-06-30 2025-04-24 Innobation Bio Co., Ltd. Humanized antibody specific for cd47 and pharmaceutical composition for preventing or treating cd47-related diseases comprising the same
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
IL316058A (en) 2022-04-21 2024-11-01 Gilead Sciences Inc Compounds modulate KRAS G12D
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024121777A1 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
TW202440151A (zh) 2022-12-09 2024-10-16 美商輝瑞大藥廠 Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法
CN118221812A (zh) * 2022-12-14 2024-06-21 上海迈石生物技术有限公司 一种靶向cd47的单克隆抗体及其应用
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
WO2024177978A1 (en) * 2023-02-24 2024-08-29 The Regents Of The University Of California Lilrb3 engager cells
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
CN117004700A (zh) * 2023-10-07 2023-11-07 北京爱博生生物技术有限公司 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5057604A (en) 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
EP0592677B1 (en) 1992-02-18 2001-11-07 Otsuka Kagaku Kabushiki Kaisha Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ253943A (en) 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
DE69432375T2 (de) 1993-04-30 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
EP0703979B1 (en) 1993-06-04 2000-09-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Method for treating kaposi's sarcoma with antisense oligonucleotides
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DK0843961T3 (da) 1995-08-29 2007-05-21 Kirin Brewery Kimærisk mus og fremgangsmåde til at producere samme
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
CA2303072A1 (en) * 1997-09-11 1999-03-18 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
WO2000053634A1 (fr) 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Fv monocatenaire induisant l'apoptose
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU2002315052A1 (en) * 2001-05-15 2002-11-25 Emory University Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
KR100454414B1 (ko) 2001-06-25 2004-10-26 주식회사 진생사이언스 산소를 이용한 개량 홍삼의 제조 방법
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
EP1530418A4 (en) 2002-05-31 2005-10-12 Univ Leland Stanford Junior METHOD FOR IDENTIFYING AND INSULATING STEM CELLS AND CANCER STAMPS
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
EP1693385A4 (en) 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
JP4970948B2 (ja) 2003-12-05 2012-07-11 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 癌幹細胞の同定、単離、および除去の方法
SI1707627T1 (sl) * 2003-12-25 2013-02-28 Kyowa Hakko Kirin Co., Ltd. Antagonistiäśen mutant anti-cd40 protitelesa
US20050288491A1 (en) * 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
ATE461708T1 (de) 2004-05-07 2010-04-15 Univ North Carolina Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
US7728880B2 (en) 2004-06-25 2010-06-01 Qualcomm Incorporated Automatic white balance method and apparatus
CA2620802A1 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
EP2027151A2 (en) * 2006-05-15 2009-02-25 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
JP5588865B2 (ja) 2007-07-31 2014-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｃｄ２０に対するヒト抗体及びその使用方法
GB2468232B (en) 2007-11-30 2012-10-24 Glaxo Group Ltd Antigen-bindng constructs
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
CA3221018A1 (en) 2008-01-15 2009-07-23 Ravindra Majeti Markers of acute myeloid leukemia stem cells
KR100962704B1 (ko) 2008-07-02 2010-06-11 유상규 일측 단말의 제어로 타 단말의 주변장치를 이용하는 단말장치 및 그 인터페이스 방법
NZ590816A (en) 2008-08-14 2013-02-22 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
EP3130674B1 (en) * 2008-11-03 2020-07-08 ADC Therapeutics SA Antibodies that specifically block the biological activity of a tumor antigen
ES2927646T3 (es) * 2009-09-15 2022-11-08 Univ Leland Stanford Junior Terapia anti-CD47 sinérgica para cánceres hematológicos
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
US20120283124A1 (en) 2009-11-10 2012-11-08 Park Christopher Y Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes
DK2569013T3 (da) 2010-05-14 2017-02-13 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer til cd47
WO2012021867A2 (en) 2010-08-13 2012-02-16 The Johns Hopkins University A comprehensive methylome map of myeloid and lymphoid commitment from hematopoietic progenitors
US20140271683A1 (en) 2010-12-21 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
CN104136037B (zh) 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
PL2812443T3 (pl) * 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
US9073996B2 (en) 2012-08-31 2015-07-07 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Also Published As

Publication number Publication date
EA201400875A1 (ru) 2015-01-30
US20150238604A1 (en) 2015-08-27
KR20200040897A (ko) 2020-04-20
PT2812443T (pt) 2019-09-05
ES2743203T3 (es) 2020-02-18
ZA201405864B (en) 2015-11-25
US20160251435A1 (en) 2016-09-01
CN104271757B (zh) 2020-06-09
MX2014009427A (es) 2015-05-11
PE20141908A1 (es) 2014-12-21
EP2812443A1 (en) 2014-12-17
EP3578569A1 (en) 2019-12-11
HK1205195A1 (en) 2015-12-11
CR20140406A (es) 2014-12-10
IL233934B (en) 2022-04-01
KR102338833B1 (ko) 2021-12-13
SG10201700160RA (en) 2017-03-30
BR112014019331A8 (pt) 2018-01-16
ME03512B (me) 2020-04-20
PH12014501758B1 (en) 2019-03-06
PL2812443T3 (pl) 2020-01-31
KR20150008049A (ko) 2015-01-21
JP2015508072A (ja) 2015-03-16
US9663575B2 (en) 2017-05-30
RS59159B1 (sr) 2019-10-31
AU2013217114B2 (en) 2017-03-30
JP6273212B2 (ja) 2018-01-31
CL2014002086A1 (es) 2015-02-27
US9045541B2 (en) 2015-06-02
ECSP14016994A (es) 2015-09-30
BR112014019331A2 (pt) 2022-07-12
SMT201900453T1 (it) 2019-11-13
LT2812443T (lt) 2019-09-10
SG11201404638SA (en) 2014-09-26
NZ628314A (en) 2017-01-27
EP2812443B1 (en) 2019-05-29
IL233934A0 (en) 2014-09-30
KR102100388B1 (ko) 2020-04-13
HUE13746964T2 (hu) 2020-01-28
AU2013217114A1 (en) 2014-09-18
EA034778B1 (ru) 2020-03-19
CN104271757A (zh) 2015-01-07
CA2863834A1 (en) 2013-08-15
CY1121911T1 (el) 2020-10-14
DK2812443T3 (da) 2019-08-26
PH12014501758A1 (en) 2014-11-10
UA116772C2 (uk) 2018-05-10
US20210317205A1 (en) 2021-10-14
WO2013119714A1 (en) 2013-08-15
MY169341A (en) 2019-03-21
CN111533804A (zh) 2020-08-14
CO7111273A2 (es) 2014-11-10
MX360772B (es) 2018-11-15
US20130224188A1 (en) 2013-08-29
SI2812443T1 (sl) 2019-10-30
EP2812443A4 (en) 2015-11-04

Similar Documents

Publication Publication Date Title
HRP20191500T1 (hr) Protutijela protiv cd47 i postupci njihove upotrebe
JP7375122B2 (ja) ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体
JP2018502060A5 (hr)
JP5972871B2 (ja) 抗ｉｌ−２３ヘテロ二量体特異的抗体
CA3048578A1 (en) Anti-cd47 antibodies and uses thereof
HRP20201191T1 (hr) Mutirani multispecifični fab fragmenti antitijela
CA3056972A1 (en) Anti-ox40 antibody and use thereof
JP2019523651A5 (hr)
JP2014526898A5 (hr)
JP2015511817A5 (hr)
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
HRP20160485T1 (hr) Anti-mezotelinska protutijela i njihova uporaba
WO2013188864A4 (en) Anti-cd22 anti-idiotypic antibodies and uses thereof
HRP20180352T1 (hr) Protutijela anti-fcrh5
CN102574923A (zh) 针对人蛋白酶激活受体-2的高亲和力人抗体
RU2018137110A (ru) Антитела против psma и их применение
JP2017532005A5 (hr)
JP2019505477A5 (hr)
JP2017511152A5 (hr)
KR101864693B1 (ko) B형 간염 바이러스의 preS1에 특이적으로 결합하는 항체 및 이의 용도
RU2016148616A (ru) Анти-lgr5 антитела и их применение
HRP20190946T1 (hr) Sredstva za liječenje trostruko negativnog raka dojke
JP2015511216A5 (hr)
RU2018129180A (ru) Тромбиновое антитело, антиген-связывающий фрагмент и их фармацевтическое применение
WO2022095934A1 (zh) 抗Siglec-15抗体及其在制备药物中的应用